Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Abbott Presents New Esmo Data Showing 30-Percent Absolute Improvement in Sensitivity with the Whole-Genome Sequencing Oncodetect Test in Colorectal Cancer CI Oct. 22 Abbott Laboratories' Q3 Somewhat a ...

Abbott Laboratories (ISIN US0028241000) saw BTIG cut its price target from USD 134.00 to USD 125.00 on October 21, 2026, ...

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its ...

The nutrition separation is anticipated to be completed by the end of 2027, structured as a tax-free distribution to ...

Wall Street's major averages finished in the red on Friday as technology stocks continued to lag amid artificial intelligence spending fears and a continued rise in oil prices due to geopolitical ...

Shares of Abbott Laboratories ABT rallied 1.99% to $102.51 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising ...

Shares in Abbott Laboratories ($ABT) were down 4% in pre-market trading today as it announced that it planned to separate its global Nutrition business into an ...

Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult ...

Abbott, which also makes diagnostics and medical devices, will spin off the unit that makes Similac and Ensure into its own ...